$CCEL
CRYO CELL INTERNATIONAL INC

2016 Q4 Form 10-Q Financial Statement

#000119312516739879 Filed on October 17, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $5.870M $6.332M $5.436M
YoY Change 1.21% 16.48% 10.09%
Cost Of Revenue $1.440M $1.551M $1.507M
YoY Change -2.04% 2.91% 0.51%
Gross Profit $4.430M $4.781M $3.929M
YoY Change 2.31% 21.69% 14.26%
Gross Profit Margin 75.47% 75.5% 72.27%
Selling, General & Admin $3.810M $3.912M $2.629M
YoY Change -0.78% 48.79% -10.83%
% of Gross Profit 86.0% 81.82% 66.92%
Research & Development $20.00K $13.78K $9.952K
YoY Change 100.0% 38.46% -44.25%
% of Gross Profit 0.45% 0.29% 0.25%
Depreciation & Amortization $70.00K $70.00K $60.00K
YoY Change 0.0% 16.67% -40.0%
% of Gross Profit 1.58% 1.46% 1.53%
Operating Expenses $3.860M $3.925M $2.639M
YoY Change -0.77% 48.75% -11.03%
Operating Profit $570.0K -$1.062M $1.264M
YoY Change 29.55% -184.0% 194.74%
Interest Expense -$140.0K $199.4K $353.5K
YoY Change -50.0% -43.59% 14.3%
% of Operating Profit -24.56% 27.96%
Other Income/Expense, Net $30.00K -$2.481M -$365.0K
YoY Change 0.0% 579.75% 219.32%
Pretax Income $350.0K -$3.543M $898.1K
YoY Change -170.0% -494.5% 242.83%
Income Tax -$460.0K -$898.8K -$6.931M
% Of Pretax Income -131.43% -771.75%
Net Earnings $810.0K -$2.644M $7.830M
YoY Change -468.18% -133.77% 3209.59%
Net Earnings / Revenue 13.8% -41.76% 144.03%
Basic Earnings Per Share -$0.35 $0.83
Diluted Earnings Per Share $118.9K -$0.35 $0.80
COMMON SHARES
Basic Shares Outstanding 6.796M shares 7.584M shares 9.462M shares
Diluted Shares Outstanding 7.584M shares 9.750M shares

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.120M $2.660M $3.180M
YoY Change -13.45% -16.35% -10.92%
Cash & Equivalents $3.500M $2.026M $2.719M
Short-Term Investments $620.0K $630.0K $460.0K
Other Short-Term Assets $78.45K $46.84K $33.90K
YoY Change -11.25% 38.16% -95.42%
Inventory $361.1K $410.9K $539.1K
Prepaid Expenses $395.5K $472.1K $447.6K
Receivables $4.053M $4.381M $4.163M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.012M $10.15M $9.907M
YoY Change -12.95% 2.4% 19.85%
LONG-TERM ASSETS
Property, Plant & Equipment $979.5K $993.4K $878.4K
YoY Change 11.42% 13.1% -13.54%
Goodwill $0.00 $111.4K $1.742M
YoY Change -100.0% -93.6%
Intangibles $261.0K $266.8K $565.5K
YoY Change -49.45% -52.82%
Long-Term Investments $0.00 $0.00 $684.0K
YoY Change -100.0% -9.85%
Other Assets $9.547M $6.404M $8.650M
YoY Change 15.5% -25.97% 949.17%
Total Long-Term Assets $10.53M $7.397M $9.528M
YoY Change 15.11% -22.37% 417.74%
TOTAL ASSETS
Total Short-Term Assets $9.012M $10.15M $9.907M
Total Long-Term Assets $10.53M $7.397M $9.528M
Total Assets $19.54M $17.54M $19.44M
YoY Change 0.21% -9.74% 92.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.485M $1.605M $1.448M
YoY Change 11.8% 10.84% 39.47%
Accrued Expenses $2.554M $1.719M $1.919M
YoY Change 27.38% -10.41% 67.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M $2.000M $300.0K
YoY Change 545.16% 566.67%
Total Short-Term Liabilities $13.11M $12.41M $10.45M
YoY Change 25.78% 18.74% 18.73%
LONG-TERM LIABILITIES
Long-Term Debt $1.425M $1.425M $2.300M
YoY Change -38.04% -38.04% 0.0%
Other Long-Term Liabilities $21.84M $22.15M $13.81M
YoY Change 55.58% 60.35% 19.86%
Total Long-Term Liabilities $23.27M $23.57M $16.11M
YoY Change 42.4% 46.3% 16.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.11M $12.41M $10.45M
Total Long-Term Liabilities $23.27M $23.57M $16.11M
Total Liabilities $34.95M $34.56M $26.56M
YoY Change 42.89% 30.09% 17.4%
SHAREHOLDERS EQUITY
Retained Earnings -$26.79M -$27.60M -$25.25M
YoY Change 5.19% 9.31% -24.13%
Common Stock $30.47M $29.51M $28.34M
YoY Change 6.33% 4.15% 23680.59%
Preferred Stock
YoY Change
Treasury Stock (at cost) $19.12M $18.99M $8.059M
YoY Change 129.91% 135.58% 70.16%
Treasury Stock Shares 5.715M shares 5.678M shares
Shareholders Equity -$15.41M -$17.02M -$4.828M
YoY Change
Total Liabilities & Shareholders Equity $19.54M $17.54M $19.44M
YoY Change 0.21% -9.74% 92.3%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income $810.0K -$2.644M $7.830M
YoY Change -468.18% -133.77% 3209.59%
Depreciation, Depletion And Amortization $70.00K $70.00K $60.00K
YoY Change 0.0% 16.67% -40.0%
Cash From Operating Activities $2.570M $1.080M $1.030M
YoY Change 29.15% 4.85% 8.42%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$10.00K -$10.00K
YoY Change -33.33% 0.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities -$30.00K $20.00K -$230.0K
YoY Change -83.33% -108.7% 1050.0%
Cash From Investing Activities -$70.00K $10.00K -$240.0K
YoY Change -70.83% -104.17% 500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.020M -3.580M -1.990M
YoY Change 218.75% 79.9% 131.4%
NET CHANGE
Cash From Operating Activities 2.570M 1.080M 1.030M
Cash From Investing Activities -70.00K 10.00K -240.0K
Cash From Financing Activities -1.020M -3.580M -1.990M
Net Change In Cash 1.480M -2.490M -1.200M
YoY Change 3.5% 107.5% -2500.0%
FREE CASH FLOW
Cash From Operating Activities $2.570M $1.080M $1.030M
Capital Expenditures -$40.00K -$10.00K -$10.00K
Free Cash Flow $2.610M $1.090M $1.040M
YoY Change 27.32% 4.81% 7.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
29389683
CY2016Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2289644
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2026199
CY2016Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
5999974
CY2016Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4381110
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000 shares
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000 shares
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6796421 shares
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000 shares
CY2016Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
9866178
CY2016Q2 ccel Repurchases Agreement Settlement Payment In Part Through Term Loan
RepurchasesAgreementSettlementPaymentInPartThroughTermLoan
8000000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2719463
CY2015Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6825413 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12504464 shares
CY2016Q3 us-gaap Assets
Assets
17542285
CY2016Q3 us-gaap Assets Current
AssetsCurrent
10145201
CY2016Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2630000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
0
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
125044
CY2016Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
12071215
CY2016Q3 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1605411
CY2016Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7086515
CY2016Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
2178000
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
55590
CY2016Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1719313
CY2016Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
8650100
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2016Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1425000
CY2016Q3 us-gaap Preferred Stock Redemption Price Per Share
PreferredStockRedemptionPricePerShare
0.01
CY2016Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
259530
CY2016Q3 us-gaap Other Assets Current
OtherAssetsCurrent
46838
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
266809
CY2016Q3 us-gaap Inventory Net
InventoryNet
410885
CY2016Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
630023
CY2016Q3 us-gaap Liabilities
Liabilities
34557554
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17542285
CY2016Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
266809
CY2016Q3 us-gaap Goodwill
Goodwill
111392
CY2016Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
81912
CY2016Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22146315
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12411239
CY2016Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
472146
CY2016Q3 us-gaap Notes Payable
NotesPayable
0
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6403675
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
14228
CY2016Q3 us-gaap Notes Payable Current
NotesPayableCurrent
2000000
CY2016Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
1666430
CY2016Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
993409
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
-17015269
CY2016Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.24
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
146270 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.86
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27599156
CY2016Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.36
CY2016Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
5678354 shares
CY2016Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
995740 shares
CY2016Q3 us-gaap Treasury Stock Value
TreasuryStockValue
18986430
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1142010 shares
CY2016Q3 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
2 CompensationPlan
CY2016Q3 ccel Deposits And Other Assets
DepositsAndOtherAssets
25500
CY2016Q3 ccel Inventory Collection Kits
InventoryCollectionKits
62933
CY2016Q3 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
17000
CY2016Q3 ccel Intangible Asset Impaired Accumulated Impairment Loss
IntangibleAssetImpairedAccumulatedImpairmentLoss
211267
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3279267
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9010322 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12260340 shares
CY2015Q4 us-gaap Assets
Assets
19497946
CY2015Q4 us-gaap Assets Current
AssetsCurrent
10353128
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2630000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
28530368
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2067130
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4152162
CY2015Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
5930987
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3058379
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
122603
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10869218
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1328619
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6782562
CY2015Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1336000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
169932
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2005351
CY2015Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
868947
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2300000
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
282152
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
88392
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
516328
CY2015Q4 us-gaap Inventory Net
InventoryNet
475608
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
610424
CY2015Q4 us-gaap Liabilities
Liabilities
24462117
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19497946
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
516328
CY2015Q4 us-gaap Goodwill
Goodwill
1777822
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
134727
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14038165
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10423952
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
427819
CY2015Q4 us-gaap Notes Payable
NotesPayable
1176367
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8265748
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
9041
CY2015Q4 us-gaap Notes Payable Current
NotesPayableCurrent
307420
CY2015Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
879070
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-4964171
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
15003 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.90
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25468991
CY2015Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
3249790 shares
CY2015Q4 us-gaap Treasury Stock Value
TreasuryStockValue
8318083
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
204344
CY2015Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
40611
CY2015Q4 ccel Inventory Collection Kits
InventoryCollectionKits
57406
CY2015Q4 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
17000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-559804
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
305000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
586675
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
76000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.86
us-gaap Adjustment For Amortization
AdjustmentForAmortization
174964
us-gaap Depreciation And Amortization
DepreciationAndAmortization
60702
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.84
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8469092
us-gaap Costs And Expenses
CostsAndExpenses
12801662
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9864
us-gaap Cost Of Services
CostOfServices
4158767
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6956834
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
214520
us-gaap Revenues
Revenues
15293260
us-gaap Noncash Or Part Noncash Acquisition Debt Assumed1
NoncashOrPartNoncashAcquisitionDebtAssumed1
1300000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1028763
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4142
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-789783
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-159163
us-gaap Licenses Revenue
LicensesRevenue
508235
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-25483
us-gaap Net Income Loss
NetIncomeLoss
8325774
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
149596
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1445175
us-gaap Interest Expense
InterestExpense
1024621
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-481562
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
143318
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
240369
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
212203
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2946705
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
455532
us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
6881000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-53746
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
247939 shares
us-gaap Operating Income Loss
OperatingIncomeLoss
2491598
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2941750
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1173443
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1462835
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-17660
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6880599
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2863508
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54691
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
148
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9945618 shares
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8549722
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9697679 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32471
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
54100
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
14519177
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
22500 shares
us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-4813
us-gaap Share Based Compensation
ShareBasedCompensation
304585
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
49145
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-10548
ccel Increase Decrease In Prepaid Expenses In Connection With Acquisition
IncreaseDecreaseInPrepaidExpensesInConnectionWithAcquisition
-104000
ccel Product Revenue
ProductRevenue
265848
dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000862692
dei Document Period End Date
DocumentPeriodEndDate
2016-08-31
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2125963
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
821000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
145000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Adjustment For Amortization
AdjustmentForAmortization
222513
us-gaap Depreciation And Amortization
DepreciationAndAmortization
123166
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2244507
us-gaap Costs And Expenses
CostsAndExpenses
17280461
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
38252
us-gaap Cost Of Services
CostOfServices
4330622
us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
287000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-842000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
202928
us-gaap Revenues
Revenues
17257192
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
1877697
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10783433
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2803999
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47968
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-186175
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
44327
us-gaap Licenses Revenue
LicensesRevenue
965977
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-41554
us-gaap Net Income Loss
NetIncomeLoss
-2130165
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
578860
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2827268
us-gaap Interest Expense
InterestExpense
804236
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-297184
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-114342
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1901591
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
300593
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
10668347
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
449541
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-64723
us-gaap Operating Income Loss
OperatingIncomeLoss
-23269
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-4253681
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1505950
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
-842000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2827268
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-697103
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2424902
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
298600
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-204344
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Product Warranty and Cryo-Cell Cares<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> Program</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February&#xA0;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Additionally, under the Cryo-Cell Cares<b><sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup></b> program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Company&#x2019;s reserve balance is based on the $75,000 or $50,000 (as applicable) maximum payment and the $10,000 maximum expense reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and the historical usage and failure rates in other private and public cord blood banks based on published data. The Company&#x2019;s estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in the estimated rates used in determining the Company&#x2019;s reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of August&#xA0;31, 2016 and November&#xA0;30, 2015 the Company recorded reserves under these programs in the amounts of approximately $17,000 and $17,000, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets.</p> </div>
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8546110 shares
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10914524
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P20D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
2017-12-05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
73462 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.87
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8546110 shares
dei Trading Symbol
TradingSymbol
CCEL
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
204729 shares
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
16004962
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34452
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40340
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
204729 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.86
us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-50023
us-gaap Share Based Compensation
ShareBasedCompensation
821416
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
Open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
One Common Share per Right
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y2M27D
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1009107
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-15111
ccel Net Cash Proceeds From Sale Of Assets Percentage
NetCashProceedsFromSaleOfAssetsPercentage
0.50 pure
ccel Gain Loss On Extinguishment Of Revenue Sharing Agreement
GainLossOnExtinguishmentOfRevenueSharingAgreement
-2252388
ccel Deferred Revenue Recognition Period
DeferredRevenueRecognitionPeriod
P12M
ccel Contracted Storage Period Option Two
ContractedStoragePeriodOptionTwo
P21Y
ccel Product Revenue
ProductRevenue
286253
ccel Associate Stock Purchase Plan Price Percentage Of Common Stock Market Price
AssociateStockPurchasePlanPricePercentageOfCommonStockMarketPrice
0.50 pure
ccel Extinguishment Of Revenue Sharing Agreements
ExtinguishmentOfRevenueSharingAgreements
3400000
ccel Number Of Deliverables For Revenue Recognized
NumberOfDeliverablesForRevenueRecognized
2 Deliverables
ccel Contracted Storage Period Option One
ContractedStoragePeriodOptionOne
P1Y
ccel Period For Doubtful Of Accounts Receivable Due From Client
PeriodForDoubtfulOfAccountsReceivableDueFromClient
P21Y
CY2015Q3 us-gaap Cost Of Services
CostOfServices
1507393
CY2015Q3 us-gaap Revenues
Revenues
5435990
ccel Types Of License Agreements
TypesOfLicenseAgreements
2 Agreement
ccel Contracted Storage Period Option Three
ContractedStoragePeriodOptionThree
Lifetime
ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50 pure
CY2015Q2 ccel Percentage Of Outstanding Common Shares Purchases Under Tender Offer
PercentageOfOutstandingCommonSharesPurchasesUnderTenderOffer
0.0776 pure
CY2015Q2 ccel Tender Offer To Purchase Common Stock Price Per Share
TenderOfferToPurchaseCommonStockPricePerShare
3.25
CY2015Q2 ccel Tender Offer Sales Price
TenderOfferSalesPrice
2.29
CY2015Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60000
CY2015Q3 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
25000
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
CY2015Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
25359
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.80
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7746614
CY2015Q3 us-gaap Costs And Expenses
CostsAndExpenses
4171674
CY2015Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8933
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-365003
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11469
CY2015Q3 us-gaap Licenses Revenue
LicensesRevenue
169411
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
7829572
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
898149
CY2015Q3 us-gaap Interest Expense
InterestExpense
353534
CY2015Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-82958
CY2015Q3 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
6931000
CY2015Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
288095 shares
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1264316
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
899313
CY2015Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1164
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6931423
CY2015Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9750197 shares
CY2015Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2628970
CY2015Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9462102 shares
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9952
CY2015Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
5000731
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
22500 shares
CY2015Q3 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-11529
CY2015Q3 ccel Product Revenue
ProductRevenue
265848
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
433000
CY2016Q3 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
91000
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2016Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
39746
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2658483
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
7394013
CY2016Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12902
CY2016Q3 us-gaap Cost Of Services
CostOfServices
1551231
CY2016Q3 us-gaap Revenues
Revenues
6331938
CY2016Q3 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
1877697
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2481124
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29297
CY2016Q3 us-gaap Licenses Revenue
LicensesRevenue
609045
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-2644361
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3543199
CY2016Q3 us-gaap Interest Expense
InterestExpense
199439
CY2016Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-14122
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1062075
CY2016Q3 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
990000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3543199
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-898838
CY2016Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7583771 shares
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3911559
CY2016Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7583771 shares
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13780
CY2016Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
5634758
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
35000 shares
CY2016Q3 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-29371
CY2016Q3 ccel Gain Loss On Extinguishment Of Revenue Sharing Agreement
GainLossOnExtinguishmentOfRevenueSharingAgreement
-2252388
CY2016Q3 ccel Product Revenue
ProductRevenue
88135

Files In Submission

Name View Source Status
0001193125-16-739879-index-headers.html Edgar Link pending
0001193125-16-739879-index.html Edgar Link pending
0001193125-16-739879.txt Edgar Link pending
0001193125-16-739879-xbrl.zip Edgar Link pending
ccel-20160831.xml Edgar Link completed
ccel-20160831.xsd Edgar Link pending
ccel-20160831_cal.xml Edgar Link unprocessable
ccel-20160831_def.xml Edgar Link unprocessable
ccel-20160831_lab.xml Edgar Link unprocessable
ccel-20160831_pre.xml Edgar Link unprocessable
d252389d10q.htm Edgar Link pending
d252389dex311.htm Edgar Link pending
d252389dex312.htm Edgar Link pending
d252389dex313.htm Edgar Link pending
d252389dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending